此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines

2026年11月16日 更新者:Longbio Pharma

A Multicenter, Randomized, Double-Blind, Active-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines

This is a multicenter, randomized, double-blind, active-controlled Phase III clinical study to evaluate the safety and efficacy of LP-003 injection in patients with chronic spontaneous urticaria who remain symptomatic despite treatment with H1 antihistamines.

研究概览

研究类型

介入性

注册 (估计的)

514

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Beijing、中国
        • Peking Union Medical College Hospital
        • 接触:
      • Shenyang、中国
        • The First Affiliated Hospital of China Medical University
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

12年 至 75年 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Have the capacity to understand the study and voluntarily signs the informed consent form (ICF);
  2. Male or female participant must be 12 to 75 years old at the time of ICF signature;
  3. Duration of chronic spontaneous urticaria (CSU) ≥ 6 months prior to screening;
  4. Presence of pruritus and wheals for at least 6 consecutive weeks before screening despite treatment with H1-AH;
  5. Participants have been on a stable dose of second-generation H1-AH as specified in the protocol for ≥2 weeks prior to randomization and within the 7 days before randomization, the UAS7( range 0-42) ≥16 and ISS7(range 0-21) ≥8;
  6. Participants must not miss UAS scores for more than one day within the 7 days prior to randomization, and are willing and able to complete daily symptom diaries during the study period.
  7. Female participants of childbearing potential, and male participants (and their female partners), must use one or more effective contraceptive measures from the screening period until at least 6 months after the last administration of investigational product. Participants must have no plans for pregnancy, sperm donation or oocyte donation from screening until at least 6 months after the last dose of investigational product.

Exclusion Criteria:

  1. The subject has a primary or sole trigger for chronic urticaria (chronic Induced urticaria), including artificial urticaria (Symptomatic Dermographism), cold, heat, sun, pressure, delayed pressure, water, cholinergic, or contact urticaria;
  2. Other medical conditions accompanied by symptoms of urticaria or angioedema including, but not limited to, urticarial vasculitis, mastocytosis, pigmented urticaria, erythema multiforme, , hereditary or acquired angioedema, etc;
  3. Any other dermatologic condition with chronic itching, such as atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis, which in the judgment of the Investigator may affect the evaluation of the study and the results of the study;
  4. Body weight < 40 kg
  5. Not enough washing-out period for previous therapy before randomization.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:LP-003 group

Participants received LP-003 subcutaneously during the 48-week treatment period

s.c. injection

有源比较器:Omalizumab group

Participants received omalizumab subcutaneously during the 48-week treatment period

s.c. injection

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change from baseline in weekly Urticaria Activity Score (UAS7) at week 12
大体时间:Week 12

The UAS7 is a composite score derived from the ISS7 and the HSS7, i.e., the sum of ISS7 and HSS7, ranging from 0 to 42 points. UAS7 = 0 indicates complete resolution of urticaria.

Week 12

次要结果测量

结果测量
措施说明
大体时间
Change from baseline in UAS7 at each assessment visit (excluding Week 12)
大体时间:up to approximately 56 weeks
up to approximately 56 weeks
The proportion of participants with UAS7 = 0 at each assessment visit
大体时间:up to approximately 56 weeks
up to approximately 56 weeks
The proportion of participants with UAS7 ≤ 6at each assessment visit
大体时间:up to approximately 56 weeks
up to approximately 56 weeks
Change From Baseline in weekly hives severity score (HSS7) at each assessment visit.
大体时间:up to approximately 56 weeks

The HSS7 is the sum of daily HSS scores over the 7 days prior to the visit, ranging from 0 to 21 points. HSS7 = 0 indicates complete resolution of hives.

up to approximately 56 weeks
Change From Baseline in weekly itch severity score ( ISS7) at each assessment visit.
大体时间:Time Frame: up to approximately 56 weeks

The ISS7 is the sum of daily ISS scores over the 7 days prior to the visit, ranging from 0 to 21 points. ISS7 = 0 indicates complete resolution of itch.

Time Frame: up to approximately 56 weeks
Change From Baseline in weekly angloedema activity score (AAS7) at each assessment visit.
大体时间:Time Frame: up to approximately 56 weeks

The AAS7 is the sum of the daily AAS scores over the 7 days prior to the visit, ranging from 0 to 105 points. AAS7 = 0 indicates no angioedema.

Time Frame: up to approximately 56 weeks
Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at each assessment visit
大体时间:up to approximately 56 weeks

The scale consists of 23 items. Each item is scored from 1 to 5 points. The total score is transformed to a scale ranging from 0 to 100, with higher scores indicating a greater impact of the disease on patients' quality of life

up to approximately 56 weeks
The incidence of adverse events during the study
大体时间:up to approximately 56 weeks

Incidence and severity of AE from first dose to end of study are recorded

up to approximately 56 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Xinghua Gao、First Hospital of China Medical University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月7日

初级完成 (估计的)

2028年3月24日

研究完成 (估计的)

2029年1月26日

研究注册日期

首次提交

2026年11月9日

首先提交符合 QC 标准的

2026年11月16日

首次发布 (实际的)

2026年11月18日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月16日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅